Alaunos Therapeutics (NASDAQ:TCRT) Issues Earnings Results

Alaunos Therapeutics (NASDAQ:TCRT) posted its quarterly earnings data on Friday. The company reported ($0.41) earnings per share for the quarter, FiscalAI reports.

Alaunos Therapeutics Price Performance

Alaunos Therapeutics stock traded down $0.06 during trading hours on Friday, hitting $1.93. The stock had a trading volume of 11,146 shares, compared to its average volume of 16,742. The stock has a market capitalization of $47.13 million, a price-to-earnings ratio of -0.91 and a beta of -1.00. Alaunos Therapeutics has a 1-year low of $1.67 and a 1-year high of $4.59. The stock’s fifty day moving average is $2.07 and its two-hundred day moving average is $2.57.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Alaunos Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Alaunos Therapeutics

A hedge fund recently raised its position in Alaunos Therapeutics stock. Geode Capital Management LLC boosted its position in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) by 25.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 19,736 shares of the company’s stock after acquiring an additional 3,945 shares during the period. Geode Capital Management LLC owned about 0.85% of Alaunos Therapeutics worth $64,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 27.72% of the company’s stock.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology.